- “Drug Stocks Inch Lower; Allergan Climbs” (Wall Street Journal)
- “Allergan profit higher; Botox sales fall” (Reuters)
- “Allergan Second-Quarter Profit Rises 23 Percent” (Bloomberg)
- “Health care reform: Liberal Democrats blast public option deal with moderates” (Chicago Tribune)
- “Medarex reports narrower 2Q loss, revenue growth” (The Associated Press, CNBC)
- “Genzyme Provides Update on Allston Landing Plant” (Press release issued by Genzyme, Genzyme.com)
- “Texas Atty Gen Seeks Drug Pricing Documents From Eli Lilly” (Wall Street Journal)
- “Anadys rockets after FDA approves trial design” (Reuters)
- “Glaxo Adds Masks to Flu Franchise, Boosting Sales From Pandemic” (Bloomberg)
- “Allergan 2Q profit jumps 23 percent on cost cuts” (The Associated Press)
- “Allergan’s 2nd-quarter profit jumps 23 percent on lower costs, offsets continuing sales drop” (Washington Examiner)
- “Allergan Reports Second Quarter 2009 Operating Results” (Press release issued by Allergan, Allergan.com)
- “Medicis Announces Second Quarter 2009 Conference Call and Webcast” (Press release issued by Medicis, Medicis.com)
- “A ‘Common Sense’ American Health Reform Plan” (The New York Times)
- “Takeda Leads Japan Drugmakers’ Revenue Lower on Stronger Yen” (Bloomberg)
- “AstraZeneca still awaiting FDA news on Onglyza” (Reuters)
- “Nasal Vaccine Holds Promise Against Swine Flu” (The New York Times)
- “Mylan says trends bolster 2010 outlook” (Reuters)
- “Exelixis Announces Second Quarter 2009 Financial Results” (Press release issued by Exelixis, Business Wire)
- “Health Reform and Cancer” (Wall Street Journal)
- “Stock costs push United Therapeutics to 2Q loss” (The Associated Press)
- “FDA OKs Roche’s Refiling For Actemra Approval” (Wall Street Journal)
- “Anadys gets FDA nod on hepatitis C drug study, shrs up” (Reuters)
- “Schering Plough’s Saphris Gets Strong Nod From FDA Panel” (The Pink Sheet)
SUBSCRIBE